Neuland Laboratories Limited — Q2FY27 earnings call summary

Filed 06 November 2026 · Official transcript

Risks include raw material cost volatility, geopolitical disruptions, and project timing variability
Capex H1 FY27 Rs.261 Cr; 3-year capex guidance ~Rs.1700-1800 Cr including peptide expansion and Kakinada land
Q2 FY27 total income Rs.457.2 Cr (-11.4% y-y); H1 FY27 Rs.1107.2 Cr (+35.5% y-y)
Peptide facility commissioned; PPQ revenues expected in 6-9 months, commercial in ~1.5-2 years
Growth expectations intact for FY27 and FY28; no precise guidance given
CMS revenue lumpy due to few large molecules; no major launches last 1 year; patent cliffs post 2030
Q2 EBITDA Rs.104.6 Cr (22.9% margin) vs Rs.156.9 Cr (30.4%) last year; PAT Rs.51.1 Cr vs Rs.96.5 Cr
R&D center at Genome Valley to enhance integrated process development for peptides and small molecules